Practice:

• Intellectual Property
• Life Sciences

Bar Admissions:

Massachusetts
U.S. Patent and Trademark Office

Experience:

Prior to joining Burns & Levinson LLP, Dr. Hasan worked at ImmunoGen Inc., where he was sole in-house patent counsel, and before that as a technology specialist at Combinatorx Inc. and Lahive & Cockfield LLP where he advised companies on patentability and trade secret matters, preparation and prosecution of U.S. and foreign patents, and management and development of a worldwide patent portfolio. Additionally, Dr. Hasan prepared non-infringement, freedom-to-operate and patentability opinions, performed due diligence evaluations, worked with the business development teams and monitored and analyzed competitive intellectual property.

Dr. Hasan’s practice focuses on biotechnology, more specifically, on human or humanized antibody technology, (e.g., IGF-IR, CD33, DS6, Muc1/16, EphA2, CD38, etc.), or oncology-based molecular biology (e.g., methods and compositions for the treatment and diagnosis of cellular proliferative disorders using novel gene products, apoptosis etc.); medicinal chemistry, such as, small molecules (e.g., maytansinoids and derivatives, mutant Actinosynnema pretiosum strain with increased maytansinoid production, prodrugs and analogs of CC1065 (pyrroloindole moieties linked by amide bonds), benzodiazepine derivatives, taxanes and their derivatives), linker-based technology (e.g., cleavable and non-cleavable, cross linkers, charged or hydrophilic linkers), processes of making such drugs or improvements thereof, making of immunoconjugates therefrom; formulations thereof; and synergistic effects on combinatorial use of two or more drugs.

Prior to entering the legal field, Dr. Hasan was a research associate for Harvard Medical School at the Dana Farber Cancer Institute studying the role of vav/slp 76 adaptors in CD28 signaling in the immune system. He was also a research fellow for Brown University School of Medicine at the Rhode Island Hospital performing research on signaling mechanisms involved in development of hepatocellular carcinoma. Dr. Hasan has experience as a research scientist in the Emerging Technology Division of Novartis Pharmaceuticals in Takarazuka, Japan, where he helped identify and characterize putative therapeutic molecules as targets for drug designing, specifically for osteoporosis and cancer metastasis.

Memberships:

• American Bar Association
• American Intellectual Property Law Association
• Boston Bar Association
• Boston Patent Law Association

Additional Information:

• Dr. Hasan is conversational in Japanese and Hindi.

Education:

• J.D., Suffolk University Law School, 2005
• Ph.D., Cancer Biology, Hokkaido University, Japan, 1994
• M.S., Environmental Medicine, Hokkaido University, Japan, 1991
• M.S., Biotechnology, Aligarh Muslim University, India, 1987
• B.S. Chemistry, Aligarh Muslim University, India, 1985

Recent Articles and Publications: